Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished

Axe Cap view

Viking Therapeutics Dips but Long Game Intact

Despite an 18.6% fall in July on cash burn fears, Viking Therapeutics' phase 3 progress keeps long-term potential alive.

Viking Therapeutics took a hit in July, dropping nearly 19%, mainly because investors worried about its hefty $96 million quarterly cash burn and a looming $500 million share raise that could dilute current holders. Yet, the company has enough funds to last through 2028 and is advancing well with its weight-loss drug trials, targeting a market hungry for effective alternatives to GLP-1s. For South Africans, the direct link is limited, but the USD/ZAR pair could react if biotech funding conditions change or if a similar local biotech story emerges. Meanwhile, companies like Naspers or Prosus don’t really touch this space, so keep Viking in a watchful corner rather than front and center. The risk here is that increased share dilution might erode value if trial results don’t meet expectations or timelines slip. Still, Viking’s potential in a booming weight-loss drug market keeps it from being a pure avoid. this is just our opinion and not financial advice